Purity estimation from differentially methylated sites using Illumina Infinium methylation microarray data.
Ontology highlight
ABSTRACT: Solid tissues collected from patient-driven clinical settings are composed of both normal and cancer cells, which often precede complications in data analysis and epigenetic findings. The Purity estimation of samples is crucial for reliable genomic aberration identification and uniform inter-sample and inter-patient comparisons as well. Here, an effective and flexible method has been developed and designed to estimate the level of methylation, which infers tumor purity without prior knowledge from the other datasets. The comprehensive analysis of our approach on Illumina Infinium 450 k methylation microarray explains that TCGA Breast Cancer data exhibits improved performance for purity assessment. This assessment has a strong correlation with other advanced methods.
SUBMITTER: Azim R
PROVIDER: S-EPMC7469651 | biostudies-literature |
REPOSITORIES: biostudies-literature
ACCESS DATA